{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:18:35Z","timestamp":1792001915455,"version":"4.4.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jtho.2025.04.013","type":"journal-article","created":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:24:18Z","timestamp":1746321858000},"page":"1315-1327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC Networks"],"prefix":"10.1016","volume":"20","author":[{"given":"Sarah","family":"Fodil-Cherif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Hadoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Carlos","family":"Benitez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Lasolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Perrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jannin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Laboureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maelle","family":"Le Bras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Gaujoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel Groussin","family":"Rouiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Hentic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Du Boullay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Haissaguerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Kinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Goudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Scoazec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Faron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2025.04.013_bib1","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.ejca.2012.12.022","article-title":"Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry","volume":"49","author":"Korse","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2025.04.013_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.annonc.2021.01.003","article-title":"Lung and thymic carcinoids: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.04.013_bib3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/SLA.0b013e3181dd4ec4","article-title":"Thymic neuroendocrine tumors: a SEER database analysis of 160 patients","volume":"251","author":"Gaur","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.jtho.2025.04.013_bib4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtcvs.2014.08.061","article-title":"Outcome of primary neuroendocrine tumors of the thymus: a joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases","volume":"149","author":"Filosso","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2025.04.013_bib5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/icvts\/ivx265","article-title":"Results of treatment for thymic neuroendocrine tumours: multicentre clinicopathological study","volume":"26","author":"Ose","year":"2018","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.jtho.2025.04.013_bib6","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007842","article-title":"Treatment, prognostic markers, and survival in thymic neuroendocrine tumors: a single center experience of 41 patients","volume":"96","author":"Ma","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jtho.2025.04.013_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227197","article-title":"Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States","volume":"14","author":"Hsu","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2025.04.013_bib8","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1530\/EJE-19-0877","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Cushing\u2019s syndrome due to ectopic ACTH secretion: an expert operational opinion","volume":"182","author":"Young","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jtho.2025.04.013_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/EJE-10-0950","article-title":"Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d\u2019etude des Tumeurs Endocrines","volume":"165","author":"Goudet","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jtho.2025.04.013_bib10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00428-021-03037-1","article-title":"Recent advances and conceptual changes in the classification of neuroendocrine tumors of the thymus","volume":"478","author":"Bohnenberger","year":"2021","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jtho.2025.04.013_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.athoracsur.2012.03.062","article-title":"Primary neuroendocrine tumors of the thymus: a multicenter experience of 35 patients","volume":"94","author":"Cardillo","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2025.04.013_bib12","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ejcts.2009.10.026","article-title":"Primary neuroendocrine tumours of the thymus: a clinicopathologic and prognostic study in 19 patients","volume":"37","author":"Cardillo","year":"2010","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2025.04.013_bib13","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.3390\/cancers14194944","article-title":"A Single Center analysis of thymic neuroendocrine tumors","volume":"14","author":"Zhai","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2025.04.013_bib14","doi-asserted-by":"crossref","first-page":"S1484","DOI":"10.21037\/jtd.2017.10.83","article-title":"Neuroendocrine tumors of the thymus","volume":"9","author":"Filosso","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jtho.2025.04.013_bib15","series-title":"Who Classification of Tumours: Thoracic Tumours","author":"Borczuk","year":"2021"},{"key":"10.1016\/j.jtho.2025.04.013_bib16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jtho.2021.10.010","article-title":"The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors?","volume":"17","author":"Marx","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.04.013_bib17","article-title":"Carcinoid\/neuroendocrine tumour of the thymus","author":"Str\u00f6bel","year":"2021"},{"key":"10.1016\/j.jtho.2025.04.013_bib18","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","article-title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2025.04.013_bib19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.athoracsur.2016.07.050","article-title":"Neuroendocrine tumors of the thymus: analysis of factors affecting survival in 254 patients","volume":"103","author":"Sullivan","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2025.04.013_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ejcts\/ezx037","article-title":"Comparison of clinical features and survival between thymic carcinoma and thymic carcinoid patients","volume":"52","author":"Zhao","year":"2017","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2025.04.013_bib21","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Follow-up study of thymomas with special reference to their clinical stages","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2025.04.013_bib22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1440-1827.1994.tb02936.x","article-title":"A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma","volume":"44","author":"Koga","year":"1994","journal-title":"Pathol Int"},{"key":"10.1016\/j.jtho.2025.04.013_bib24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000472255","article-title":"Thymic neuroendocrine neoplasms: biological behaviour and therapy","volume":"105","author":"Jia","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.jtho.2025.04.013_bib25","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jtho.2019.02.002","article-title":"Characterization, prognosis, and treatment of patients with metastatic lung carcinoid tumors","volume":"14","author":"Robelin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.04.013_bib26","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/S1470-2045(17)30681-2","article-title":"Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial","volume":"18","author":"Ferolla","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.04.013_bib27","doi-asserted-by":"crossref","first-page":"S1448","DOI":"10.21037\/jtd.2017.02.02","article-title":"Neuroendocrine tumors of the thymus and mediastinum","volume":"9","author":"Bohnenberger","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jtho.2025.04.013_bib28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.lungcan.2020.08.001","article-title":"Lung carcinoids with high proliferative activity: further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms","volume":"148","author":"Rubino","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.04.013_bib29","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jtho.2019.04.015","article-title":"Molecular classification of neuroendocrine tumors of the thymus","volume":"14","author":"Dinter","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.04.013_bib30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12022-021-09668-z","article-title":"Molecular pathology of well-differentiated pulmonary and thymic neuroendocrine tumors: what do pathologists need to know?","volume":"32","author":"Volante","year":"2021","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.jtho.2025.04.013_bib31","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s41379-019-0248-2","article-title":"Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices","volume":"32","author":"Rekhtman","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2025.04.013_bib32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13023-022-02366-x","article-title":"Real-world clinicopathological features and outcome of thymic neuroendocrine tumors: a retrospective single-institution analysis","volume":"17","author":"Chen","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jtho.2025.04.013_bib33","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/1759-7714.12868","article-title":"Evaluation of the prognostic value of surgery and postoperative radiotherapy for patients with thymic neuroendocrine tumors: a propensity-matched study based on the SEER database","volume":"9","author":"Wen","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtho.2025.04.013_bib34","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.athoracsur.2017.05.011","article-title":"Adjuvant chemotherapy does not confer superior survival in patients with atypical carcinoid tumors","volume":"104","author":"Anderson","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2025.04.013_bib35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/COC.0b013e318209a8f8","article-title":"Efficacy and tolerability of long-acting octreotide in the treatment of thymic tumors: results of a pilot trial","volume":"35","author":"Longo","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.04.013_bib36","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.04.013_bib37","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.04.013_bib38","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2023.03.024","article-title":"Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data","volume":"186","author":"Boil\u00e8ve","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2025.04.013_bib39","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1159\/000526811","article-title":"Efficacy and safety of lanreotide autogel and temozolomide combination therapy in progressive thoracic neuroendocrine tumors (carcinoid): results from the Phase 2 ATLANT study","volume":"113","author":"Ferolla","year":"2023","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.jtho.2025.04.013_bib40","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1634\/theoncologist.2019-0361","article-title":"Capecitabine and temozolomide in advanced lung neuroendocrine neoplasms","volume":"25","author":"Al-Toubah","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2025.04.013_bib41","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1159\/000444087","article-title":"Oxaliplatin-based chemotherapy in advanced neuroendocrine tumors: clinical outcomes and preliminary correlation with biological factors","volume":"103","author":"Spada","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.jtho.2025.04.013_bib42","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1200\/JCO.23.02724","article-title":"Oxaliplatin-based versus alkylating agent in neuroendocrine tumors according to the O6-methylguanine-DNA methyltransferase status: a randomized Phase II study (MGMT-NET)","volume":"43","author":"Walter","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.04.013_bib43","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3390\/curroncol30020106","article-title":"Prospective evaluation of MGMT-promoter methylation status and correlations with outcomes to temozolomide-based chemotherapy in well-differentiated neuroendocrine tumors","volume":"30","author":"Brighi","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jtho.2025.04.013_bib44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.lungcan.2012.12.001","article-title":"Treatment, prognostic markers and survival in thymic neuroendocrine tumours. A study from a single tertiary referral centre","volume":"79","author":"Crona","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.04.013_bib45","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1210\/jc.2014-1560","article-title":"Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients","volume":"99","author":"de Laat","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jtho.2025.04.013_bib46","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1097\/JTO.0b013e3181f13682","article-title":"Standard outcome measures for thymic malignancies","volume":"5","author":"Huang","year":"2010","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425007026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425007026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T20:29:55Z","timestamp":1772483395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086425007026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1556086425007026"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2025.04.013","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC Networks","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}]}}